{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:16:37Z","timestamp":1790982997474,"version":"4.1.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,5]]},"DOI":"10.7759\/cureus.114015","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T16:23:50Z","timestamp":1785947030000},"source":"Crossref","is-referenced-by-count":1,"title":["Psoriasiform Dermatitis Following JAK Inhibitor Therapy for Hidradenitis Suppurativa and Crohn\u2019s Disease"],"prefix":"10.7759","author":[{"given":"Gerardo S","family":"Caussade-Silvestrini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina  P","family":"Gerena-Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael E","family":"Rodr\u00edguez-Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia A","family":"Alvarado-Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio E","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19556","article-title":"Aetiology and pathogenesis of hidradenitis suppurativa","volume":"183","author":"Wolk K","year":"2020","unstructured":"Wolk K, Join-Lambert O, Sabat R. Aetiology and pathogenesis of hidradenitis suppurativa. Br J Dermatol. 2020, 183:999-1010. 10.1111\/bjd.19556","journal-title":"Br J Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.12.046","article-title":"Improvements in moderate-to-severe hidradenitis suppurativa with upadacitinib: results from a phase 2, randomized, placebo-controlled study","volume":"92","author":"Ackerman LS","year":"2025","unstructured":"Ackerman LS, Schlosser BJ, Zhan T, et al.. Improvements in moderate-to-severe hidradenitis suppurativa with upadacitinib: results from a phase 2, randomized, placebo-controlled study. J Am Acad Dermatol. 2025, 92:1252-60. 10.1016\/j.jaad.2024.12.046","journal-title":"J Am Acad Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2024.08.002","article-title":"The utility of upadacitinib to treat refractory hidradenitis suppurativa in an obese patient","volume":"65","author":"Islam Z","year":"2025","unstructured":"Islam Z, Ch'en PY, Choi S, Oprea Y, Campton K. The utility of upadacitinib to treat refractory hidradenitis suppurativa in an obese patient. JAAD Case Rep. 2025, 65:102-4. 10.1016\/j.jdcr.2024.08.002","journal-title":"JAAD Case Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1341632","article-title":"Application of JAK inhibitors in paradoxical reaction through immune-related dermatoses","volume":"15","author":"Zhang Y","year":"2024","unstructured":"Zhang Y, Jiang G. Application of JAK inhibitors in paradoxical reaction through immune-related dermatoses. Front Immunol. 2024, 15:1341632. 10.3389\/fimmu.2024.1341632","journal-title":"Front Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/life15071026","article-title":"Psoriasiform dermatitis: from pathogenesis to new therapeutic opportunities","volume":"15","author":"Di Brizzi EV","year":"2025","unstructured":"Di Brizzi EV, Caccavale S, Giorgio CM, Argenziano G, Balato A. Psoriasiform dermatitis: from pathogenesis to new therapeutic opportunities. Life (Basel). 2025, 15:1026. 10.3390\/life15071026","journal-title":"Life (Basel)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2016.12.006","article-title":"Psoriasiform dermatitides: a brief review","volume":"34","author":"Wick MR","year":"2017","unstructured":"Wick MR. Psoriasiform dermatitides: a brief review. Semin Diagn Pathol. 2017, 34:220-5. 10.1053\/j.semdp.2016.12.006","journal-title":"Semin Diagn Pathol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.932766","article-title":"Case report: Clinical and histopathological characteristics of psoriasiform erythema and de novo IL-17A cytokines expression on lesioned skin in atopic dermatitis children treated with dupilumab","volume":"9","author":"Ali K","year":"2022","unstructured":"Ali K, Wu L, Qiu Y, Li M. Case report: Clinical and histopathological characteristics of psoriasiform erythema and de novo IL-17A cytokines expression on lesioned skin in atopic dermatitis children treated with dupilumab. Front Med (Lausanne). 2022, 9:932766. 10.3389\/fmed.2022.932766","journal-title":"Front Med (Lausanne)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16883","article-title":"Review article: paradoxical psoriasis as a consequence of tumour necrosis factor antagonists in patients with inflammatory bowel disease","volume":"55","author":"Townsend CM","year":"2022","unstructured":"Townsend CM, Lovegrove F, Khanna R, Wilson AS. Review article: paradoxical psoriasis as a consequence of tumour necrosis factor antagonists in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2022, 55:1379-88. 10.1111\/apt.16883","journal-title":"Aliment Pharmacol Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon A","year":"2019","unstructured":"Rendon A, Sch\u00e4kel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019, 20:1475. 10.3390\/ijms20061475","journal-title":"Int J Mol Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v9.i15.3506","article-title":"Association of hidradenitis suppurativa with Crohn's disease","volume":"9","author":"Zhang M","year":"2021","unstructured":"Zhang M, Chen QD, Xu HX, Xu YM, Chen HJ, Yang BL. Association of hidradenitis suppurativa with Crohn's disease. World J Clin Cases. 2021, 9:3506-16. 10.12998\/wjcc.v9.i15.3506","journal-title":"World J Clin Cases"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-45. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/508931-psoriasiform-dermatitis-following-jak-inhibitor-therapy-for-hidradenitis-suppurativa-and-crohns-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T16:23:51Z","timestamp":1785947031000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/508931-psoriasiform-dermatitis-following-jak-inhibitor-therapy-for-hidradenitis-suppurativa-and-crohns-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.114015","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,5]]}}}